Zealand Pharma Announces Topline Results From 13-Week Phase 1b Multiple Ascending Dose Clinical Trial With GLP-1/GLP-2 Receptor Dual Agonist Dapiglutide; Placebo-Adjusted Reductions In Body Weight Of Up To A Mean Of 8.3% With Dapiglutide After 13 Weekly Doses
Portfolio Pulse from Benzinga Newsdesk
Zealand Pharma announced positive results from a Phase 1b trial of dapiglutide, showing significant weight reduction and good tolerability. The trial is ongoing with higher doses being tested, and results are expected in 2025.
September 09, 2024 | 3:04 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Zealand Pharma's dapiglutide demonstrated significant weight reduction in a Phase 1b trial, with good safety and tolerability. This positive result could boost investor confidence and impact stock prices favorably.
The positive topline results from the Phase 1b trial of dapiglutide, showing significant weight reduction and good tolerability, are likely to boost investor confidence in Zealand Pharma. The ongoing trial with higher doses and expected results in 2025 could further impact the stock positively if successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100